Matrisome Properties of Scaffolds Direct Fibroblasts in Idiopathic Pulmonary Fibrosis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
17 Aug 2019
Historique:
received: 12 07 2019
revised: 09 08 2019
accepted: 15 08 2019
entrez: 21 8 2019
pubmed: 21 8 2019
medline: 6 2 2020
Statut: epublish

Résumé

In idiopathic pulmonary fibrosis (IPF) structural properties of the extracellular matrix (ECM) are altered and influence cellular responses through cell-matrix interactions. Scaffolds (decellularized tissue) derived from subpleural healthy and IPF lungs were examined regarding biomechanical properties and ECM composition of proteins (the matrisome). Scaffolds were repopulated with healthy fibroblasts cultured under static stretch with heavy isotope amino acids (SILAC), to examine newly synthesized proteins over time. IPF scaffolds were characterized by increased tissue density, stiffness, ultimate force, and differential expressions of matrisome proteins compared to healthy scaffolds. Collagens, proteoglycans, and ECM glycoproteins were increased in IPF scaffolds, however while specific basement membrane (BM) proteins such as laminins and collagen IV were decreased, nidogen-2 was also increased. Findings were confirmed with histology, clearly showing a disorganized BM. Fibroblasts produced scaffold-specific proteins mimicking preexisting scaffold composition, where 11 out of 20 BM proteins were differentially expressed, along with increased periostin and proteoglycans production. We demonstrate how matrisome changes affect fibroblast activity using novel approaches to study temporal differences, where IPF scaffolds support a disorganized BM and upregulation of disease-associated proteins. These matrix-directed cellular responses emphasize the IPF matrisome and specifically the BM components as important factors for disease progression.

Identifiants

pubmed: 31426504
pii: ijms20164013
doi: 10.3390/ijms20164013
pmc: PMC6719040
pii:
doi:

Substances chimiques

Calcium-Binding Proteins 0
Cell Adhesion Molecules 0
Extracellular Matrix Proteins 0
Glycoproteins 0
Laminin 0
NID2 protein, human 0
Proteoglycans 0
Collagen 9007-34-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Stiftelsen för Strategisk Forskning
ID : SBE13-0130
Organisme : Vetenskapsrådet
ID : 2016-01190
Organisme : Swedish Heart-Lung Foundation
ID : 20140293
Organisme : Kungliga Fysiografiska Sällskapet i Lund
ID : not available
Organisme : The Crafoord Foundation
ID : not available
Organisme : Greta and John Kock Foundation
ID : not available
Organisme : Alfred Österlunds Stiftelse
ID : not available
Organisme : Åke och Inger Bergkvist foundation
ID : not available
Organisme : Medicinska Fakulteten, Lunds Universitet
ID : not available
Organisme : ALF
ID : not available
Organisme : Stiftelsen Olle Engkvist Byggmästare
ID : not available

Références

Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1327-34
pubmed: 11350814
Int J Biochem Cell Biol. 2004 Aug;36(8):1573-84
pubmed: 15147736
Nat Rev Mol Cell Biol. 2006 Apr;7(4):265-75
pubmed: 16607289
J Invest Dermatol. 2007 Mar;127(3):545-54
pubmed: 17008882
Biochem Soc Trans. 2007 Aug;35(Pt 4):695-7
pubmed: 17635125
Exp Biol Med (Maywood). 2007 Oct;232(9):1121-9
pubmed: 17895520
Int J Biochem Cell Biol. 2008;40(10):2129-40
pubmed: 18374622
Proc Am Thorac Soc. 2008 Apr 15;5(3):305-10
pubmed: 18403324
Hum Pathol. 2008 Sep;39(9):1275-94
pubmed: 18706349
Eur Respir J. 2009 Jan;33(1):77-84
pubmed: 18829682
J Biol Chem. 2010 Jan 15;285(3):2028-39
pubmed: 19887451
FASEB J. 2010 Jun;24(6):1838-51
pubmed: 20097873
Respir Res. 2010 May 11;11:55
pubmed: 20459817
J Cell Biol. 2010 Aug 23;190(4):693-706
pubmed: 20733059
Cells Tissues Organs. 2012;195(3):222-31
pubmed: 21502745
J Exp Med. 2011 Jul 4;208(7):1459-71
pubmed: 21708929
J Biol Chem. 2011 Sep 30;286(39):34298-310
pubmed: 21828051
Cold Spring Harb Perspect Biol. 2012 Jan 01;4(1):a004903
pubmed: 21937732
Mol Cell Proteomics. 2012 Apr;11(4):M111.014647
pubmed: 22159717
Am J Respir Crit Care Med. 2012 Nov 1;186(9):866-76
pubmed: 22936357
Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15;303(12):L1046-56
pubmed: 23043074
Mol Biol Cell. 2014 Jan;25(1):87-94
pubmed: 24173714
J Clin Invest. 2014 Apr;124(4):1622-35
pubmed: 24590289
Nat Biotechnol. 2014 Mar;32(3):223-6
pubmed: 24727771
J Mech Behav Biomed Mater. 2014 Sep;37:186-95
pubmed: 24946269
BMC Pulm Med. 2014 Jul 26;14:120
pubmed: 25064447
Am J Respir Cell Mol Biol. 2015 Apr;52(4):503-12
pubmed: 25188360
Ann Biomed Eng. 2015 Mar;43(3):568-76
pubmed: 25344351
Biomater Sci. 2014 May 1;2(5):634-650
pubmed: 25379176
Clin Cosmet Investig Dermatol. 2014 Nov 06;7:301-11
pubmed: 25395868
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L344-57
pubmed: 25502501
Lancet Respir Med. 2015 Jun;3(6):462-72
pubmed: 25770676
Matrix Biol. 2015 May-Jul;44-46:247-54
pubmed: 25805621
Matrix Biol. 2016 Jan;49:10-24
pubmed: 26163349
Respir Res. 2016 Mar 04;17:23
pubmed: 26944412
Nat Commun. 2016 Jun 03;7:11703
pubmed: 27256716
Acta Biomater. 2016 Dec;46:91-100
pubmed: 27693690
Int J Biochem Cell Biol. 2017 Feb;83:27-38
pubmed: 27974233
Lancet. 2017 May 13;389(10082):1941-1952
pubmed: 28365056
Physiol Rep. 2017 May;5(9):null
pubmed: 28507166
ACS Nano. 2017 Jul 25;11(7):7110-7117
pubmed: 28699736
Cell Mol Life Sci. 2017 Dec;74(23):4305-4314
pubmed: 28918442
Nat Rev Drug Discov. 2017 Oct 30;16(11):810
pubmed: 29081515
Matrix Biol. 2018 Nov;73:64-76
pubmed: 29274939
Curr Rheumatol Rep. 2018 Jan 19;20(1):2
pubmed: 29349703
J Proteomics. 2018 Oct 30;189:23-33
pubmed: 29501846
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L59-L65
pubmed: 29516782
Sci Rep. 2018 Apr 3;8(1):5409
pubmed: 29615673
Front Med (Lausanne). 2018 Jul 02;5:148
pubmed: 30013972
Clin Proteomics. 2019 Feb 6;16:6
pubmed: 30774578
Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1819-28
pubmed: 8970376

Auteurs

Linda Elowsson Rendin (L)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden. linda.elowsson_rendin@med.lu.se.

Anna Löfdahl (A)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden.

Emma Åhrman (E)

Division of Infection Medicine Proteomics, Department Clinical Sciences, Lund University, Lund 221 84, Sweden.

Catharina Müller (C)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden.

Thomas Notermans (T)

Department of Biomedical engineering, Lund University, Lund 221 84, Sweden.

Barbora Michaliková (B)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden.

Oskar Rosmark (O)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden.

Xiao-Hong Zhou (XH)

Bioscience Department, Respiratory, Inflammation and Autoimmunity, IMED Biotech Unit, AstraZeneca, Mölndal 431 53, Sweden.

Göran Dellgren (G)

Department of Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.

Martin Silverborn (M)

Department of Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.

Leif Bjermer (L)

Department of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University, Lund 221 85, Sweden.

Anders Malmström (A)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden.

Anna-Karin Larsson-Callerfelt (AK)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden.

Hanna Isaksson (H)

Department of Biomedical engineering, Lund University, Lund 221 84, Sweden.

Johan Malmström (J)

Division of Infection Medicine Proteomics, Department Clinical Sciences, Lund University, Lund 221 84, Sweden.

Gunilla Westergren-Thorsson (G)

Lung Biology, Department of Experimental Medical Sciences, Lund University, BMC C12, Lund 221 84, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH